FY2024 EPS Estimates for MediWound Cut by HC Wainwright

MediWound Ltd. (NASDAQ:MDWD) – Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of MediWound in a note issued to investors on Wednesday, November 27th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of ($2.61) for the year, down from their previous forecast of ($2.14). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.47) per share. HC Wainwright also issued estimates for MediWound’s Q4 2024 earnings at ($0.54) EPS, Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($1.87) EPS, FY2027 earnings at ($0.80) EPS and FY2028 earnings at $1.06 EPS.

MediWound (NASDAQ:MDWD) last released its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the firm posted ($0.24) EPS.

MediWound Stock Performance

MDWD stock opened at $18.42 on Monday. The company’s fifty day moving average price is $17.19 and its 200-day moving average price is $17.39. MediWound has a one year low of $8.81 and a one year high of $24.00. The company has a market capitalization of $198.75 million, a PE ratio of -6.35 and a beta of 0.81.

Hedge Funds Weigh In On MediWound

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Investor AB bought a new stake in MediWound in the third quarter worth $15,750,000. Rosalind Advisors Inc. raised its stake in shares of MediWound by 22.3% in the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock valued at $11,343,000 after acquiring an additional 114,560 shares during the period. ARK Investment Management LLC bought a new stake in shares of MediWound in the 3rd quarter worth about $1,806,000. State Street Corp boosted its stake in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 45,529 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in MediWound during the 2nd quarter valued at about $342,000. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.